Study of Capecitabine Therapy in Advanced Cancer
Author Information
Author(s): D. Santini, B. Vincenzi, G. Schiavon, A. La Cesa, S. Gasparro, A. Vincenzi, G. Tonini
Primary Institution: University Campus Bio-Medico, Rome, Italy
Hypothesis
What is the maximum-tolerated dose of chronomodulated capecitabine in patients with advanced cancer?
Conclusion
High doses of chronomodulated capecitabine can be administered with acceptable toxicity and show evidence of antitumor activity.
Supporting Evidence
- Patients were assessable for toxicity, with only one episode of dose-limiting toxicity observed.
- Six partial responses were noted in breast cancer patients and three in colorectal cancer patients.
- The recommended dose for further studies was established at 2,750 mg/m2.
Takeaway
Doctors tested a new way to give a cancer medicine called capecitabine, and it worked well for many patients without making them too sick.
Methodology
Patients received capecitabine in a specific schedule for two weeks followed by a week of rest, and their responses and side effects were monitored.
Limitations
The study was limited to a small sample size and did not primarily focus on tumor response.
Participant Demographics
Median age was 68 years, with a range of 49 to 88 years; 9 men and 18 women.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website